Polycythemia Vera

Is Jakafi Right for Me?


How do I know if I am a possible candidate for treatment with Jakafi?

Jakafi® (ruxolitinib) is a prescription medicine that has been FDA approved for adults with polycythemia vera (PV) who have already taken a medicine called hydroxyurea (HU) and it did not work well enough or they could not tolerate it.

HU is a type of chemotherapy drug that may be used to help reduce the number of blood cells in some people with PV. However, not all people will benefit from HU or be able to tolerate it.

Jakafi is not chemotherapy. It is a targeted treatment that works to help keep the production of blood cells under control. Learn more about how Jakafi works


When should I discuss possible changes in my current treatment plan with my Healthcare Professional?

You should be discussing any changes in how you feel with your Healthcare Professional regularly.

If you have questions or concerns about any of the factors listed above, be sure to talk with your Healthcare Professional to determine if it may be time to discuss an alternate treatment approach—which may or may not include Jakafi.

Patient Perspectives: Lee’s Story

image of Lee

As a former triathlete, Lee had always been in tune with his body. When his current PV treatment wasn’t working well enough, his instincts led him to explore what was possible with Jakafi.

If you have PV and have already taken HU and it did not work well enough for you or you were unable to tolerate it, you may be a possible candidate for Jakafi. Talk to your Healthcare Professional to find out if Jakafi may be right for you.


How do I know if treatment with HU is not working well enough for me?

If you are taking HU and are having trouble with increased blood counts or burdensome side effects from HU, talk with your Healthcare Professional. It may be time to discover if Jakafi may be right for you.


What are possible side effects of Jakafi?

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

Professional Perspective:

How Do I Know If Hydroxyurea is Not Right for Me?

Listen to a myeloproliferative neoplasm (MPN) expert discuss the challenges that patients with PV may experience when treated with a chemotherapy medicine called hydroxyurea.

Watch Now

Image of woman – Jakafi patient – talking on the phone, sitting on a park bench

Talk with a patient taking Jakafi

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Learn How

Interested in becoming an Incyte Mentor?
Learn about the Ambassadors for Jakafi program.

Image of a Healthcare Professional sittingat a desk talking with a patient about IncyteCARES – patient support program

Already taking Jakafi? IncyteCARES is a patient support program for people taking Jakafi that offers ongoing education and resources

IncyteCARES: Connecting to Access, Reimbursement, Education and Support

Learn More
connect-patient

Connect With
a Patient
Like Cam

Connect With a
Patient Like Cam

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Email Address

Continue Registering

Expand Collapse

INDICATIONS AND USAGE

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.